VistaGen Therapeutics News

VistaGen Therapeutics Aktie VALOR 25212189 / ISIN US92840H2022

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

14.01.25	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia (Businesswire)
10.01.25	Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder (Businesswire)
14.11.24	Vistagen to Present at the Stifel 2024 Healthcare Conference (Businesswire)
07.11.24	Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update (Businesswire)
05.11.24	Vistagen to Present at the 2024 Neuroscience Education Institute Congress (Businesswire)
01.11.24	Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 (Businesswire)
09.10.24	Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day (Businesswire)
23.09.24	Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder (Businesswire)
13.08.24	Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update (Businesswire)
06.08.24	Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 (Businesswire)
09.07.24	Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine (Businesswire)
27.06.24	Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year (Businesswire)
11.06.24	Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update (Businesswire)
07.06.24	Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 (Businesswire)
29.05.24	Vistagen to Present at the Jefferies Global Healthcare Conference (Businesswire)
23.05.24	Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference (Businesswire)
07.05.24	Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference (Businesswire)
25.04.24	Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue (Businesswire)
09.04.24	Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference (Businesswire)
01.04.24	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 (Businesswire)
11.03.24	Vistagen to Present at Stifel 2024 Virtual CNS Days (Businesswire)
28.02.24	Vistagen to Present at TD Cowen 44th Annual Health Care Conference (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	32.75	2.02 %	K V
Logitech Intl	69.58	1.64 %	K V
Zurich Insur Gr	559.60	1.38 %	K V
Holcim	70.86	1.34 %	K V
ABB	70.52	0.77 %	K V
Givaudan	3’061.00	-0.58 %	K V
Alcon	60.56	-0.72 %	K V
Sika	155.15	-0.74 %	K V
Swisscom	697.00	-0.78 %	K V